ABSTRACT

Background: African-Americans have the highest overall cancer death rate and shortest survival time of any racial or ethnic group in the United States. The most common cancer studied in African-American radiation therapy (RT) access disparities research is breast cancer. The goal of this study is to evaluate the impact of patient navigation on RT access for African-American breast cancer patients.

Material and methods: This study is a prospective survey-based evaluation of the impact of patient navigation on access to hypofractionated RT and financial toxicity in African-American breast cancer patients. The impact of patient navigation on RT access will be collated and analyzed from survey results pre-RT versus post-RT as well as for patients with versus without receipt of patient navigation. The validated COST-Functional Assessment of Chronic Illness Therapy score will be used to compare hypofractionation versus standard fractionated RT financial toxicity for patients with early-stage breast cancer who have received lumpectomy.

Conclusion: This is the first study to investigate the impact of patient navigation on reducing RT access disparities facing African-American breast cancer patients. The natural progression of this work will be to expand this model to include additional breast cancer populations most vulnerable to suffering RT access disparities (Native American, Hispanic American, Appalachian) within the United States.

Key words: breast cancer; adjuvant radiation therapy; African-American race; hypofractionation; patient navigation; health disparities

Rep Pract Oncol Radiother 2022;27(3):583–588
Introduction

African-Americans have disparately limited access to optimal cancer care

Despite residing in the most opulent nation on earth (2021 gross domestic product exceeding 22 trillion dollars), African-Americans have been plagued with the reality of disparately limited access to optimal medical intervention, even when Level I evidence has demonstrated the superiority of said intervention. This has unfortunately been demonstrated repeatedly in many aspects of procedure-based treatment, remaining prevalent even after accounting for income and insurance status [1–5], and has manifested in some instances as being disproportionately triaged to lower-reimbursement treatment modalities [6, 7].

The field of Radiation Oncology in the 21st century has markedly increased its role in patient care, as advances in the precision of radiation delivery have allowed advanced techniques to provide comparable outcomes to operative intervention for many cancer patients [8]. As a result, any disparity in access to radiation therapy (RT) will prove more harmful now than at any previous era.

African-Americans have the highest overall cancer death rate and shortest survival time of any racial or ethnic group in the United States [9]. Elucidation of disparities in access to cancer care are important since previous work has indicated that when equal access to RT in Radiation Therapy Oncology Group (RTOG) prospective randomized trials is granted, race does not independently affect outcomes [10], a finding similar to Level I clinical data assessing evidence-proven optimal management of curable neurologic conditions [11].

Breast cancer is the most common cancer in African-American women

The most common cancer studied in African-American RT access disparities research has been breast cancer, which is by far the most common diagnosed form of cancer among African-American women (32%) [9, 12]. Health disparities research in Radiation Oncology is a relatively new field of study; as of 2016 more than 70% of Radiation Oncology disparities peer-reviewed work had been published since the beginning of 2014 [8] — this number has likely substantially increased given the relative explosion of interest in Radiation Oncology diversity, equity and inclusion since 2016.

As such, breast cancer provides a prime opportunity to address barriers impeding equal access to treatments which improve quality-of-life, reduce financial toxicity and increase overall survival. The equivalence of breast conservation therapy including radiation as compared to mastectomy for early-stage disease has been established for more than 40 years while indications for post-mastectomy radiation have expanded in the past decade, making RT essential in the optimal treatment of breast cancer [13].

Based on the Early Breast Cancer Trialists’ Collaborative Group landmark meta-analysis (nearly 11,000 patients from 17 randomized trials), it is well-established that radiation treatment not only offers a substantial improvement in local control of breast cancer but also improves overall survival from this disease [14]. As a result, any access disparity facing African-Americans which restricts optimal radiation use results in consequences that are at least deleterious and at worst fatal.

The appropriate use of optimal RT is essential in reducing the rate of local recurrence in the conserved breast, which has further been associated with reduction of 15-year overall mortality [15]. Although there is a range of RT techniques for providing optimal breast cancer treatment, standard of care regimens for whole breast RT prescribe either at least 46 Gray (Gy) in 1.8–2.0 Gy/fraction given over 5–7 weeks as “standard fractionation”, or at least 40 Gy in 2.66–2.70 Gy/fraction given over 3–4 weeks as “hypofractionation” [16, 17].

African-American breast cancer patients are less likely to receive standard-of-care radiation therapy

Previous work has identified that compared to Caucasian women with breast cancer, African-American women are 48% more likely to have RT omission during treatment [18], 167% less likely to receive timely completion of RT after breast-conserving surgery [19], 40% less likely to complete RT [20], and significantly more likely to experience RT treatment delays [21]. Furthermore, African-American patients with Stage I breast cancer are significantly less likely to receive post-lumpectomy RT [22], and are more likely to be adversely impacted by increased distance from a cancer center with
regard to RT use [18], possibly related to a significantly increased likelihood of reliance on public transportation [20].

**Shorter course radiation therapy may reduce disparities in radiation therapy care facing African-American breast cancer patients**

With equivalent outcome and side-effect profiles between hypofractionated and standard fractionation breast cancer RT regimens firmly established by Level I evidence [15, 23], the 30–40% reduction in overall treatment time provided by hypofractionation reduces acute toxicities such as pain and fatigue and increases RT completion rates by 42-fold compared to standard fractionation [24, 25]. The impact of hypofractionation on alleviating the monetary burden of cancer care for African-American patients cannot be overstated, particularly given the present landscape where income disparity in the United States (the top 0.1% of incomes equaling the bottom 90%) even before the COVID19 pandemic was approaching a rate not seen since prior to the Great Depression [26].

As of 2017, median Caucasian household income is 86 times more than that of African-Americans and projected to increase to 99 times by 2024 [27] — these projections were before the COVID19 pandemic, which has only exacerbated underlying racial disparities. Furthermore, prospective analysis has demonstrated African-Americans receive hypofractionation following breast-conserving surgery less frequently than Caucasians [28]. It is therefore not surprising that African-Americans suffer disproportionate financial toxicity following RT compared to Caucasian patients [29, 30].

While moderate hypofractionation over 3–4 weeks has steadily increased in the United States by approximately 5% per year since 2004 [24], recent Level I evidence provided by the FAST-Forward trial has established the noninferiority of an even more extremely hypofractionated regimen. That trial compared 1 week versus 3 weeks of hypofractionation in treating early-stage breast cancer at five years post-treatment as measured by ipsilateral breast tumor recurrence rate [31]. Additionally, the one-week regimen of 26 Gy in 5 fractions demonstrated non-inferiority of local control compared to a three-week regimen (40 Gy in 15 fractions) while providing a comparably low risk of normal tissue effects/breast shrinkage compared to the 40 Gy regimen [31].

These findings offer a tremendous opportunity to potentially further decrease the duration of radiation therapy in this patient population [32] and, consequently, further reduce financial toxicity and increase treatment completion rates without compromising tumor control or normal tissue effects; this has been noted in the recently published European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations [33]. Given documented race-related differences in pain following breast radiation therapy, reducing toxicity may benefit African-American women more [34]. Although the radiation oncology community remains divided as to whether sufficient evidence exists to support the use of one-week regimens of hypofractionated adjuvant RT for breast cancer after breast-conserving surgery, the abundant evidence to support 3-week moderately hypofractionated regimens has led to consensus guidelines explicitly naming that approach as preferred over conventional fractionation for most patients receiving whole breast irradiation [35].

**Innovation**

We are implementing a patient navigator model in a novel manner to increase access to hypofractionated RT, termed the Navigator-Assisted Hypofractionation (NAVAH) program. NAVAH is highly innovative in that it is the first to use: 1) patient navigation to increase hypofractionation, 2) targeted recruitment of the African-American breast cancer community for hypofractionation, 3) objective assessment of financial toxicity experienced by African-Americans receiving conventional versus hypofractionated RT.

A culturally sensitive survey developed in cooperation with the Walking Forward program [36] will provide documentation of barriers (both real and perceived) of African-American breast cancer patients to patient navigation and results will be objectively quantified. Subsequently, the impact of patient navigation on RT access will be collated and analyzed from survey results pre-RT versus post-RT as well as for patients with versus without receipt of patient navigation. Finally, the validated COST-Functional Assessment of Chronic Illness
Therapy score will be distributed to patients following completion of RT [37] to compare financial toxicity after hypofractionation versus standard fractionated RT financial toxicity for patients with early-stage breast cancer who have received lumpectomy.

These findings from NAVAH will provide important insights into objectively quantified barriers faced by African-American breast cancer patients in receiving RT, the impact of patient navigation on these barriers, and the financial toxicity of standard versus hypofractionated RT. The natural progression of this work will be to expand this model to include additional breast cancer populations most vulnerable to suffering RT access disparities within the United States (Native American, Hispanic American, Appalachian) previously described [38–40], and eventually other common malignancies, such as prostate cancer, another common cancer where evidence to support hypofractionated regimens has been accumulating and disparities in outcomes remain substantial. Further progression will involve formal clinical trial investigation towards actively addressing barriers in receipt of RT.

Conflicts of Interest: Dr. McClelland has received travel funding from GT Medical Technologies, Inc. Dr. Harris has received an honorarium from Physician Education Resource as a speaker for the School of Breast Oncology. Dr. Spratt receives research funding from the National Institutes of Health and the Prostate Cancer Foundation and personal fees from AstraZeneca, Bayer, Blue Earth, Boston Scientific, GT Medical Technologies Inc., Janssen, Novartis, and Varian. Dr. Jagsi has stock options as compensation for her advisory board role in Equity Quotient, a company that evaluates culture in health care companies; she has received personal fees from the National Institutes of Health as a special government employee (in her role as a member of the Advisory Committee for Research on Women’s Health), the Greenwall Foundation, and the Doris Duke Charitable Foundation. She has received grants for unrelated work from the National Institutes of Health, the Doris Duke Charitable Foundation, and the Doris Duke Charitable Foundation. She has received grants for unrelated work from the National Institutes of Health, the Doris Duke Charitable Foundation, the Greenwall Foundation, the Komen Foundation, and Blue Cross Blue Shield of Michigan for the Michigan Radiation Oncology Quality Consortium. She had a contract to conduct an investigator initiated study with Genentech. She has served as an expert witness for Sherinian and Hasso, Dressman Benzinger LaVelle, and Kleinbard LLC. Dr. Petereit is the president emeritus of the American Brachytherapy Society and receives research funding from Bristol Meyers Squibb Foundation, Polo Ralph Lauren, the Irving A Hansen Memorial Foundation, and the National Institutes of Health. No other author has any conflicts of interest.

Source of Financial Support/Funding Statement: The NAVAH program is sponsored by the University Hospitals Cleveland Medical Center Department of Radiation Oncology.

Conflict of interest
None declared.

Funding
None declared.

Acknowledgments
None declared.

Author contributions
Conception and design: McClelland, Jagsi, Petereit; manuscript writing: McClelland.
Study coordination: McClelland, Harris, Spratt, Cheatham, Petereit; final approval of manuscript: all authors.

References
1. Shavers VL, Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst. 2002; 94(5): 334–357, doi: 10.1093/jnci/94.5.334, indexed in Pubmed: 11880473.
2. Morris AM, Wei Y, Birkmeyer NJ, et al. Racial disparities in late survival after rectal cancer surgery. J Am Coll Surg. 2006; 203(6): 787–794, doi: 10.1016/j.jamcollsurg.2006.08.005, indexed in Pubmed: 17116545.
3. Fatima N, Shin JH, Curry WT, et al. Racial, ethnic and socioeconomic disparities in the treatment of brain tumors. J Neurooncol. 2009; 93(1): 25–39, doi: 10.1007/s11060-009-9840-5, indexed in Pubmed: 19430880.
4. McClelland S, Guo H, Okuyemi KS. Racial disparities in the surgical management of intractable temporal lobe epilepsy in the United States: a population-based analysis. Arch Neurol. 2010; 67(5): 577–583, doi: 10.1001/archneurol.2010.86, indexed in Pubmed: 20457957.
5. Steele CB, Pisu M, Richardson LC. Urban/rural patterns in receipt of treatment for non-small cell lung cancer among black and white Medicare beneficiaries, 2000-2003. J Natl Med Assoc. 2011; 103(8): 711–718, doi: 10.1016/s0027-9684(15)30410-7, indexed in Pubmed: 22046848.
6. McClelland S, Marascalchi B, Passias P, et al. Impact of Race and Insurance Status on Surgical Approach for Cervical
Spondylotic Myelopathy in the United States. Spine. 2017; 42(3): 186–194, doi: 10.1097/BRS.0000000000001693.

7. Ryoo JJ, Batech M, Zheng C, et al. Radiotherapy for brain metastases near the end of life in an integrated health care system. Ann Palliat Med. 2017; 6(Suppl 1): S28–S38, doi: 10.21037/apm.2017.03.04, indexed in Pubmed: 28595434.

8. McClelland S, Deville C, Thomas C, et al. An overview of disparities research in access to radiation oncology care. J Radiat Oncol. 2016; 5(4): 437–444, doi: 10.1007/s13566-016-0284-1.

9. American Cancer Society. Cancer Facts & Figures for African Americans 2016–2018. American Cancer Society, Atlanta 2016.

10. Roach M, Lu J, Pilepich M, et al. Race and Survival of Men Treated for Prostate Cancer on Radiation Therapy Oncology Group Phase III Randomized Trials. The Journal of Urology. 2003: 245–250, doi: 10.1097/00004019-2003020100-00058.

11. McClelland S, Guo H, Okuyemi KS. Population-based analysis of morbidity and mortality following surgery for intractable temporal lobe epilepsy in the United States. Arch Neurol. 2011; 68(6): 725–729, doi: 10.1001/archneurol.2011.7, indexed in Pubmed: 21320984.

12. McClelland S, Page BR, Jaboin JJ, et al. The pervasive crisis of diminishing radiation therapy access for vulnerable populations in the United States, part 1: African-American patients. Adv Radiat Oncol. 2017; 2(4): 523–531, doi: 10.1016/j.adro.2017.07.002, indexed in Pubmed: 29204518.

13. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002; 347(16): 1233–1241, doi: 10.1056/NEJMoa022152, indexed in Pubmed: 12393820.

14. Darby S, McGale P, Correa C, et al. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011; 378(9804): 1707–1716, doi: 10.1016/S0140-6736(11)61629-2, indexed in Pubmed: 22019144.

15. Clarke M, Collins R, Darby S, et al. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 366(9503): 2087–2106, doi: 10.1016/S0140-6736(05)67887-7, indexed in Pubmed: 16360786.

16. Whelan TJ, Pignon JP, Levine MN, et al. Long-term results of hypofractionated radiotherapy treatment for breast cancer. N Engl J Med. 2010; 362(6): 513–520, doi: 10.1056/NEJMoa0906260, indexed in Pubmed: 20147717.

17. Smith BD, Bellon JR, Blitzblau R, et al. Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Pract Radiat Oncol. 2018; 8(3): 145–152, doi: 10.1016/j.prro.2018.01.012, indexed in Pubmed: 29545124.

18. Mandelblatt JS, Kerner JF, Hadley J, et al. OPTIONS (Outcomes and Preferences for Treatment in Older Women Nationwide Study). Variations in breast cancer treatment in older medicare beneficiaries: is it black or white. Cancer. 2002; 95(7): 1401–1414, doi: 10.1002/cncr.10825, indexed in Pubmed: 12237908.

19. Powers BD, Montes JA, Nguyen DC, et al. Demographic risk factors impacting timely radiation therapy completion after breast conserving surgery. Am J Surg. 2015; 210(5): 891–895, doi: 10.1016/j.amjsurg.2015.04.023, indexed in Pubmed: 26282892.

20. Voti L, Richardson LC, Reis IM, et al. Treatment of local breast carcinoma in Florida: the role of the distance to radiation therapy facilities. Cancer. 2006; 106(1): 201–207, doi: 10.1002/cncr.21557, indexed in Pubmed: 16311987.

21. Freedman RA, He Y, Winer EP, et al. Racial/Ethnic differences in receipt of timely adjuvant therapy for older women with breast cancer: are delays influenced by the hospitals where patients obtain surgical care? Health Serv Res. 2013; 48(5): 1669–1683, doi: 10.1111/1475-6773.12063, indexed in Pubmed: 23663229.

22. Yeboa DN, Xu X, Jones BA, et al. Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer: 2004–2009. Am J Clin Oncol. 2016; 39(6): 568–574, doi: 10.1097/COC.0000000000000994, indexed in Pubmed: 24879475.

23. Haviland JS, Mannino M, Griffin C, et al. START Trialists’ Group, START Trialists’ Group, START Trialists’ Group, START Trialists’ Group. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008; 371(9618): 1098–1107, doi: 10.1016/S0140-6736(08)60348-7, indexed in Pubmed: 18355913.

24. McClelland S, Burney HN, Zellars RC, et al. Predictors of Whole Breast Radiation Therapy Completion in Early Stage Breast Cancer Following Lumpectomy. Clin Breast Cancer. 2020; 20(6): 469–479, doi: 10.1016/j.clbc.2020.06.006, indexed in Pubmed: 32693964.

25. Jagsi R, Griffith KA, Boike TP, et al. Differences in the Acute Toxic Effects of Breast Radiotherapy by Fractionation Schedule: Comparative Analysis of Physician-Assessed and Patient-Reported Outcomes in a Large Multicenter Cohort. JAMA Oncol. 2015; 1(7): 918–930, doi: 10.1001/jamaoncol.2015.2590, indexed in Pubmed: 26247417.

26. Dalio R. Our biggest economic, social, and political issue. https://www.linkedin.com/pulse/our-biggest-economic-social-political-issue-two-economies-ray-dalio (March 9, 2019).

27. Collins C, Asante-Muhammad D, Hoxie J, Nieves E. The road to zero wealth: how the racial wealth divide is hollowing out America’s middle class. The road to zero wealth: how the racial wealth divide is hollowing out America’s middle class. (August 10, 2019).

28. Laucis AM, Jagsi R, Griffith KA, et al. Michigan Radiation Oncology Quality Consortium. The Role of Facility Variation on Racial Disparities in Use of Hypofractionated Whole Breast Radiation Therapy. Int J Radiat Oncol Biol Phys. 2020; 107(5): 949–958, doi: 10.1016/j.ijrobp.2020.04.035, indexed in Pubmed: 32376311.

29. Jagsi R, Pottow JAE, Griffith KA, et al. Long-term financial burden of breast cancer: experiences of a diverse cohort of survivors identified through population-based registries. J Clin Oncol. 2014; 32(12): 1269–1276, doi: 10.1200/JCO.2013.53.0956, indexed in Pubmed: 24663041.

30. Palmer JD, Patel TT, Eldredge-Hindy H, et al. Patients Undergoing Radiation Therapy Are at Risk of Financial Toxic...
ity: A Patient-based Prospective Survey Study. Int J Radiat Oncol Biol Phys. 2018; 101(2): 299–305, doi: 10.1016/j.ijrobp.2018.03.014, indexed in Pubmed: 29726359.

31. Murray Brunt A, Haviland JS, Wheatley DA, et al. FAST-Forward Trial Management Group. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet. 2020; 395(10237): 1613–1626, doi: 10.1016/s0140-6736(20)30932-6, indexed in Pubmed: 32580883.

32. Douek M, De Silva Minor S, Davies L, et al. Breast cancer radiation therapy. Lancet. 2020; 396(10262): 1558–1559, doi: 10.1016/s0140-6736(20)32324-2, indexed in Pubmed: 33189171.

33. Meattini I, Becherini C, Boersma L, et al. European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer. Lancet Oncol. 2022; 23(1): e21–e31, doi: 10.1016/S1470-2045(21)00539-8, indexed in Pubmed: 34973228.

34. Jagsi R, Griffith K, Vicini F, et al. Toward Improving Patients’ Experiences of Acute Toxicity From Breast Radiotherapy: Insights From the Analysis of Patient-Reported Outcomes in a Large Multicenter Cohort. J Clin Oncol. 2020; 38(34): 4019–4029, doi: 10.1200/jco.20.01703, indexed in Pubmed: 32986529.

35. Smith BD, Bellon JR, Blitzblau R, et al. Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Pract Radiat Oncol. 2018; 8(3): 145–152, doi: 10.1016/j.prro.2018.01.012, indexed in Pubmed: 29545124.

36. Peterie DG, Rogers D, Govern F, et al. Increasing access to clinical cancer trials and emerging technologies for minority populations: the Native American Project. J Clin Oncol. 2004; 22(22): 4452–4455, doi: 10.1200/JCO.2004.01.119, indexed in Pubmed: 15542797.

37. D’Rumo KA, Miller L, TenNapel MJ, et al. Assessing the financial toxicity of radiation oncology patients using the validated comprehensive score for financial toxicity as a patient-reported outcome. Pract Radiat Oncol. 2020; 10(5): e322–e329, doi: 10.1016/j.prro.2019.10.005, indexed in Pubmed: 31634632.

38. McClelland S, Leberknight J, Guadagnolo BA, et al. The pervasive crisis of diminishing radiation therapy access for vulnerable populations in the United States, part 2: American Indian patients. Adv Radiat Oncol. 2018; 3(1): 3–7, doi: 10.1016/j.adro.2017.08.010, indexed in Pubmed: 29556572.

39. McClelland S, Perez CA. The pervasive crisis of diminishing radiation therapy access for vulnerable populations in the United States—part 3: Hispanic-American patients. Adv Radiat Oncol. 2018; 3(2): 93–99, doi: 10.1016/j.adro.2017.12.003, indexed in Pubmed: 29904731.

40. McClelland S, Kaleem T, Bernard ME, et al. The pervasive crisis of diminishing radiation therapy access for vulnerable populations in the United States—Part 4: Appalachian patients. Adv Radiat Oncol. 2018; 3(4): 471–477, doi: 10.1016/j.adro.2018.08.001, indexed in Pubmed: 30370344.